Gregory Ball, DO
Pulmonary Disease · Twin Falls, IDNPI 1407985278
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,559, 2.1 times the $733 reported in 2019.
Across 372 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$565
- Actelion Pharmaceuticals US, Inc.$514
- Grifols USA, LLC$505
- United Therapeutics Corporation$383
- Sanofi$322
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,20593%
- Education$3887%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 117 | $1,140 |
| AstraZeneca(2 entities) | 31 | $565 |
| Actelion Pharmaceuticals US, Inc. | 30 | $514 |
| Grifols USA, LLC | 27 | $505 |
| United Therapeutics Corporation | 26 | $383 |
| Sanofi | 19 | $322 |
| Boehringer Ingelheim | 19 | $280 |
| Sanofi-aventis U.S. LLC | 3 | $249 |
| Mylan Specialty L.p. | 11 | $201 |
| Philips North America LLC | 11 | $181 |
| Insmed, Inc. | 8 | $180 |
| Electromed, Inc. | 8 | $154 |
| Merck | 7 | $127 |
| Sunovion Pharmaceuticals Inc. | 14 | $124 |
| Regeneron Healthcare Solutions, Inc. | 6 | $117 |
| Amgen | 4 | $71 |
| Verona Pharma, Inc. | 3 | $53 |
| Viatris Specialty LLC | 3 | $52 |
| Bayer | 3 | $44 |
| Johnson & Johnson | 3 | $43 |
| Pulmonx Corporation | 2 | $42 |
| Baxter Healthcare | 2 | $41 |
| Novartis | 2 | $37 |
| Veran Medical Technologies, Inc. | 3 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 2 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Vapotherm Inc | 1 | $13 |
| Gilead | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
How this compares
$5,593 in reported general payments places this provider in the 80th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $306,930 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 149 | $131,156 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $122,792 |
| Ambrisentan | 11 | $50,471 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $42,502 |
| Spiriva RespimatTiotropium Bromide | 27 | $21,556 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $13,105 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,616 |
| Sildenafil Citrate | 16 | $10,002 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,918 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,253 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,475 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 84 | $7,051 |
| Arnuity ElliptaFluticasone Furoate | 16 | $6,862 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $6,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $280 | $335,96267 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,140 | $171,657236 claims |
| Grifols USA, LLCProlastin C | $505 | $122,79213 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $565 | $57,307102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Twin Falls
- Shawn FrenchTwin Falls$26K
- Gary DrizinTwin Falls$3K
- Joseph EzerTwin Falls$0
- Todd HoopmanCoeur D Alene$76K
- Allen SalemIdaho Falls$44K
- Mark RasmusBoise$44K
- Karen MillerMeridian$12K
- Wesley PidcockNampa$12K
- Norman EastBoise$11K
- Jordan CormierIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.